Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

PHASE3UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

August 31, 2013

Conditions
Hepatocellular,Carcinoma
Interventions
DRUG

Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )

mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days

DRUG

the placebo ,chemotherapy(mitomycin, and Fluorouracil )

mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days

Trial Locations (1)

200032

Fudan University Zhongshan Hospital, Shanghai

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Medpace, Inc.

INDUSTRY

lead

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

INDUSTRY